Relief Effects of Icariin on Inflammation-Induced Decrease of Tight Junctions in Intestinal Epithelial Cells

Yanli Li, Jie Liu, Pawin Pongkorpsakol, Zhengguo Xiong, Xuemei Jiang, Haixia Zhao, Ding Yuan, Changcheng Zhang, Yuhui Guo, Yaoyan DunFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates how Icariin (ICA), a natural compound, protects the intestinal barrier from damage caused by inflammation, particularly in aging. Researchers found that ICA reduces inflammatory cytokines and oxidative stress in aging rats, and in cell models, it reverses the negative effects of TNF-α on tight junctions by downregulating miR-122a.

What Problem Does This Paper Address?

The intestinal barrier is crucial for health, preventing harmful substances from entering the bloodstream. This barrier is maintained by tight junctions between epithelial cells. In aging and inflammatory conditions like colitis, this barrier function is compromised due to increased inflammatory cytokines (like TNF-α and IL-1β) and oxidative stress, leading to "leaky gut." While Icariin (ICA) is known for its anti-inflammatory and antioxidant properties, its specific mechanism in restoring intestinal barrier function, especially in the context of aging and cytokine-induced damage, was not fully understood. This paper aims to elucidate how ICA protects tight junctions and the underlying molecular mechanisms, particularly focusing on the role of microRNAs.

Methods

The researchers employed a multi-pronged approach:

  • Network Pharmacology: They used computational tools (Swiss Target Prediction, GeneCards, DisGeNET, String, Cytoscape, DAVID) to predict potential drug targets of ICA for colitis and analyze their interactions and associated pathways (like KEGG). This helped identify pathways related to oxidative stress.
  • In Vivo Study (Aging Rats): They used Sprague Dawley rats, divided into adult, aging, and aging groups treated with low-dose (ICA-L) or high-dose (ICA-H) Icariin. They assessed:
  • Colonic Morphology: Histological examination (HE staining) to observe structural changes.
  • Inflammatory Cytokines: Western blot to measure TNF-α and IL-1β protein levels.
  • Tight Junction Proteins: Immunohistochemistry (IHC) and Western blot to assess Occludin, Claudin-1, and Claudin-5 expression.
  • Antioxidant Enzymes: Biochemical assays for Superoxide Dismutase (SOD), Catalase (CAT), and Glutathione Peroxidase (GSH-Px) activity.
  • Antioxidant Proteins: Western blot for Heme Oxygenase 1 (HO-1) and NADPH Quinone Acceptor Oxidoreductase 1 (NQO-1).
  • In Vitro Study (Caco-2 Cell Monolayers): Human colon cancer cells (Caco-2) were cultured to form a differentiated monolayer, mimicking the intestinal epithelium. They assessed:
  • Monolayer Integrity: Intestinal Alkaline Phosphatase (IAP) activity and Transepithelial Electrical Resistance (TEER) to confirm barrier formation.
  • Cell Viability: MTT assay to ensure TNF-α treatment didn't cause cell death.
  • TNF-α Induced Damage: Immunofluorescence (IF) to visualize Occludin protein localization and expression after TNF-α treatment.
  • Protective Effects of ICA: Western blot and qPCR to measure Occludin protein and mRNA levels, IF for Occludin localization, and permeability assays (4-KD FITC-dextran flux and TEER) to evaluate barrier function after ICA treatment.
  • MicroRNA Analysis: qPCR to measure the expression of specific microRNAs (miR-122a, miR-200c, miR-144, miR-429) after TNF-α and ICA treatment.
  • Mechanism Validation: Transfection of Caco-2 cells with miR-122a mimics to overexpress it and then assess the impact on Occludin expression and barrier function in the presence of ICA and TNF-α.

Datasets

Not explicitly discussed as distinct datasets. The study utilized standard cell lines (Caco-2) and animal models (Sprague Dawley rats). The network pharmacology analysis relied on public databases like GeneCards and DisGeNET.

Key Insights and Ideas

  • Aging and Inflammation Link: The study reinforces the connection between aging, increased inflammatory cytokines (TNF-α, IL-1β), oxidative stress, and compromised intestinal barrier function.
  • ICA's Dual Action: Icariin appears to combat intestinal barrier dysfunction through two main mechanisms: reducing inflammation and alleviating oxidative stress.
  • miR-122a as a Key Mediator: The research strongly implicates miR-122a as a critical player in TNF-α-induced tight junction damage. TNF-α upregulates miR-122a, which then targets and degrades Occludin mRNA, leading to barrier disruption.
  • ICA's miR-122a Targeting: ICA's protective effect on tight junctions seems to be mediated, at least in part, by its ability to downregulate the expression of miR-122a.
  • Translational Potential: The findings suggest ICA could be a promising therapeutic agent for conditions characterized by intestinal inflammation and barrier dysfunction, such as inflammatory bowel disease and age-related gut issues.

Key Results

  • In Vivo (Aging Rats):
    • Aging rats showed increased inflammatory cytokines (TNF-α, IL-1β) and impaired tight junction proteins (Occludin, Claudin-1, Claudin-5) compared to young rats.
  • ICA treatment reversed these changes, reducing inflammatory cytokines and upregulating tight junction proteins and antioxidant enzymes (SOD, CAT, GSH-Px, HO-1, NQO-1).
  • In Vitro (Caco-2 Cells):
    • TNF-α treatment significantly decreased Occludin protein and mRNA expression and increased intestinal permeability (higher FITC-dextran flux, lower TEER).
  • ICA treatment reversed TNF-α-induced Occludin downregulation and restored barrier function.
  • TNF-α significantly upregulated miR-122a expression, which was reversed by ICA. Other tested miRNAs (miR-200c, miR-144, miR-429) were not significantly affected.
  • Overexpressing miR-122a in Caco-2 cells mimicked the negative effects of TNF-α, reducing Occludin and increasing permeability, and importantly, it attenuated the protective effects of ICA.

Limitations and Future Work

  • In Vivo miR-122a Analysis: The study did not directly measure miR-122a expression in the colonic epithelium of aging rats, which would strengthen the link between in vivo and in vitro findings.
  • Mechanism of miR-122a Upregulation: The exact trigger for miR-122a upregulation by inflammation remains unclear and warrants further investigation.
  • Universality of ICA's Effect: The study primarily used Caco-2 cells. Future work could explore ICA's effects on other cell lines to confirm its broad applicability.
  • NF-κB Pathway: The authors suggest exploring whether ICA regulates miR-122a expression via the NF-κB pathway, which is activated by TNF-α and influences tight junction genes.
  • Potential Signaling Pathways: Further investigation into the signaling pathways (AMPK, PI3K/AKT, HIF, Foxo4) identified by network pharmacology could provide a more comprehensive understanding of ICA's actions.

Summary updated

Abstract

Inflammatory cytokines including TNF-α and IL-1β impair intestinal barrier function in aging by disrupting intestinal tight junction integrity. Icariin (ICA) has a variety of pharmacological effects. Indeed, ICA produces anti-inflammatory, anti-oxidative stress, and inhibitory effects on microRNA (miRNA) expression. This study was to explore whether ICA could alleviate inflammation-associated intestinal barrier function impairment in aging and its underlying mechanism. Of particular interest, network pharmacology prediction indicated the potential therapeutic impacts of ICA for the treatment of colitis. Then, rats were used to study whether ICA has a protective effect on the reduction of tight junctions caused by inflammatory cytokines. Next, Caco-2 cell monolayers were used to explore the mechanism by which ICA alleviates the down-regulation of tight junctions. Network pharmacology prediction revealed that ICA alleviated colitis <i>via</i> suppressing oxidative stress. After ICA intervention, expressions of inflammatory cytokines were reduced, but tight junctions, antioxidant enzymes in aging rats were up-regulated. ICA reversed the TNF-α-induced decrease in abundance of Occludin protein in Caco-2 cell monolayers. Meanwhile, ICA alleviated the increase in permeability and expression of miR-122a. However, the protective effect of ICA was markedly attenuated after transfection with miR-122a mimics. In conclusion, ICA reduced the expressions of Occludin, Claudin1, and Claudin5 in colon, which were related to the reduction of TNF-α and IL-1β and alleviation of colonic in <i>vivore</i>. And ICA attenuated TNF-α-induced Occludin disruption and epithelial barrier impairment by decreasing miR-122a expression in Caco-2 cell monolayers.
BibTeX
@inproceedings{li2022relief,
  author = {Yanli Li and Jie Liu and Pawin Pongkorpsakol and Zhengguo Xiong and Li Li and Xuemei Jiang and Haixia Zhao and Ding Yuan and Changcheng Zhang and Yuhui Guo and Yaoyan Dun},
  title = {{Relief Effects of Icariin on Inflammation-Induced Decrease of Tight Junctions in Intestinal Epithelial Cells}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.903762},
}
Figure